Azurity Pharmaceuticals

About

Azurity Pharmaceuticals' journey began with a clear focus on addressing the unmet needs of often overlooked patient populations. The company was formed in May 2019 through the strategic acquisition of Silvergate Pharmaceuticals by CutisPharma. This union brought together two entities already dedicated to developing and providing customized, user-friendly drug formulations, particularly for pediatric and geriatric patients who may struggle with conventional dosage forms like tablets and capsules. CutisPharma itself had a history of innovation, marked by the FDA approval and launch of FIRVANQ® (vancomycin hydrochloride) for oral solution in early 2018. Similarly, Silvergate Pharmaceuticals had been actively working on new drug applications, signaling a commitment to expanding therapeutic options. From its inception, Azurity set out to build upon this legacy, aiming to make safe, high-quality treatments more accessible. The company established its corporate headquarters in the Greater Boston area, specifically Woburn, MA, with manufacturing facilities also in the region (Wilmington, MA). Its early mission was significantly bolstered by the combined resources and capabilities inherited from CutisPharma and Silvergate. Over the years, Azurity has continued to grow, not just organically through its research and development efforts, but also through strategic acquisitions. A notable acquisition was Slayback Pharma in September 2023, which enhanced Azurity's development pipeline and R&D capabilities. This was followed by the significant acquisition of Covis Pharma Group in March 2025, further expanding Azurity's global footprint to over 50 countries and diversifying its portfolio across numerous therapeutic areas and complex dosage forms. This series of strategic moves underscores Azurity's commitment to becoming a key partner for global life sciences companies and accelerating the development and commercialization of necessary medicines for underserved patients worldwide. Today, Azurity Pharmaceuticals stands as a privately held company with a broad portfolio of marketed brands, leveraging data, analytics, and AI-driven digital tools to enhance its market reach and serve millions of patients globally.